End-of-day quote
Taipei Exchange
06:00:00 2024-06-26 pm EDT
|
5-day change
|
1st Jan Change
|
30
TWD
|
-2.12%
|
|
+12.99%
|
+0.84%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
1,750
|
1,546
|
2,798
|
2,885
|
3,261
|
3,232
|
Enterprise Value (EV)
1 |
1,402
|
1,365
|
2,320
|
2,554
|
2,806
|
2,532
|
P/E ratio
|
-5.52
x
|
-6.24
x
|
-15.7
x
|
-16.6
x
|
-13.8
x
|
-18
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1,889
x
|
2,106
x
|
6,205
x
|
527
x
|
108
x
|
1,271
x
|
EV / Revenue
|
1,514
x
|
1,860
x
|
5,143
x
|
466
x
|
93.3
x
|
996
x
|
EV / EBITDA
|
-5.28
x
|
-6.33
x
|
-13.8
x
|
-15.5
x
|
-14.1
x
|
-11.1
x
|
EV / FCF
|
-10.4
x
|
-13.2
x
|
-26
x
|
-26.4
x
|
-25.2
x
|
28.1
x
|
FCF Yield
|
-9.65%
|
-7.57%
|
-3.84%
|
-3.78%
|
-3.97%
|
3.55%
|
Price to Book
|
1.14
x
|
1.19
x
|
1.81
x
|
2.12
x
|
2.26
x
|
2.53
x
|
Nbr of stocks (in thousands)
|
75,739
|
75,957
|
97,508
|
97,482
|
107,098
|
108,640
|
Reference price
2 |
23.10
|
20.35
|
28.70
|
29.60
|
30.45
|
29.75
|
Announcement Date
|
3/28/19
|
3/30/20
|
3/24/21
|
3/28/22
|
3/31/23
|
3/19/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
0.926
|
0.734
|
0.451
|
5.475
|
30.08
|
2.542
|
EBITDA
1 |
-265.8
|
-215.8
|
-167.5
|
-164.9
|
-199
|
-228.7
|
EBIT
1 |
-321.6
|
-269.9
|
-214.1
|
-194.9
|
-238.9
|
-259.9
|
Operating Margin
|
-34,727.97%
|
-36,766.08%
|
-47,476.5%
|
-3,560.33%
|
-794.24%
|
-10,222.82%
|
Earnings before Tax (EBT)
1 |
-317.6
|
-246.7
|
-161.4
|
-172.5
|
-219.8
|
-163.7
|
Net income
1 |
-316.9
|
-247.2
|
-162.7
|
-172.5
|
-219.8
|
-178.4
|
Net margin
|
-34,227.11%
|
-33,682.15%
|
-36,082.26%
|
-3,150.56%
|
-730.67%
|
-7,016.6%
|
EPS
2 |
-4.185
|
-3.260
|
-1.832
|
-1.780
|
-2.210
|
-1.654
|
Free Cash Flow
1 |
-135.4
|
-103.3
|
-89.06
|
-96.62
|
-111.4
|
89.98
|
FCF margin
|
-14,617.31%
|
-14,077.86%
|
-19,747.37%
|
-1,764.8%
|
-370.4%
|
3,539.57%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/28/19
|
3/30/20
|
3/24/21
|
3/28/22
|
3/31/23
|
3/19/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
347
|
180
|
479
|
332
|
455
|
700
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-135
|
-103
|
-89.1
|
-96.6
|
-111
|
90
|
ROE (net income / shareholders' equity)
|
-18.8%
|
-17.5%
|
-11.5%
|
-11.9%
|
-15.7%
|
-13.1%
|
ROA (Net income/ Total Assets)
|
-11.7%
|
-11.7%
|
-9.21%
|
-8.21%
|
-9.6%
|
-9.93%
|
Assets
1 |
2,703
|
2,121
|
1,767
|
2,102
|
2,290
|
1,795
|
Book Value Per Share
2 |
20.20
|
17.10
|
15.90
|
13.90
|
13.50
|
11.70
|
Cash Flow per Share
2 |
3.380
|
1.560
|
1.570
|
1.280
|
0.7700
|
1.380
|
Capex
1 |
3.22
|
1.5
|
1.87
|
6.84
|
8.69
|
23.4
|
Capex / Sales
|
347.73%
|
203.81%
|
415.08%
|
124.91%
|
28.88%
|
921.32%
|
Announcement Date
|
3/28/19
|
3/30/20
|
3/24/21
|
3/28/22
|
3/31/23
|
3/19/24
|
|
1st Jan change
|
Capi.
|
---|
| +0.84% | 100M | | +38.85% | 39.1B | | -7.65% | 38.76B | | +26.86% | 31.24B | | +11.60% | 25.9B | | -13.75% | 25.8B | | +45.38% | 14.06B | | +39.82% | 13.12B | | -6.21% | 11.32B | | -12.39% | 10.68B |
Other Biotechnology & Medical Research
|